The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Khabarova N.V.

Nauchno-issledovatel'skiĭ otdel NOK tsentra "Metabolicheskiĭ sindrom" NITs GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Modern approaches to risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy

Authors:

Khabarova N.V.

More about the authors

Read: 3303 times


To cite this article:

Khabarova NV. Modern approaches to risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2014;7(3):44‑48. (In Russ.)

Recommended articles:
Clinical mani­festation of apical hype­rtrophic cardiomyopathy by syncope in the elde­rly. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):237-243
Transapical myectomy in a child with hype­rtrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):357-362

References:

  1. Belenkov YU.N., Privalova E.V., Kaplunova V.YU. Gipertroficheskaya kardiomiopatiya [Hypertrophic cardiomiopathy]. M: GEHOTАR 2011. (in Russian)
  2. Karpov R.S., Puzyrev K.V., Pavlyukova E.N., Stepanov V.А. Molekulyarno-geneticheskij analiz gipertrofii miokarda levogo zheludochka [Molecular genetic analysis of left ventricular hypertrophy]. Kardiologiya 2001; 6: 25-30. (in Russian)
  3. Kiselev I.O., Fedorov V.V., SHlyakhto E.V. Molekulyarno-geneticheskie mekhanizmy razvitiya gipertroficheskoj kardiomiopatii [Molecular and genetic mechanisms of hypertrophic cardiomyopathy]. Аrterial'naya gipertenziya 2000; 6: 44-51. (in Russian)
  4. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation 2011; 124: 783-831.
  5. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophyc Cardiomyopathy. Eur Heart J 2003; 24: 1965-1991.
  6. Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in Hypertrophic cardiomiopathy. J Am Coll Cardiol 2005; 45: 697-704.
  7. Adabag A.S., Maron B.J., Appelbaum E. et al. Occurence and freqency of arrhytmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-1374.
  8. Anan R., Greve G., Thierfelder L. et al. Prognostic implications of novel beta myosin heavy chain gene mutation that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93: 280-285.
  9. Bos J.M., Maron B.J., Ackerman M.J. et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in Hypertrophic cardiomiopathy. Am J Cardiol 2010; 106: 1481-1486.
  10. Cannan C.R., Reeder G.S., Bailey K.R. et al. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995; 92: 2488-2495.
  11. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hyperthrophic cardiomiopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13: 1283-1288.
  12. Cecci F., Olivotto I., Montereggi A. et al. Hypertropyic Cardiomyopathy in Tuscany: clinical course and outcome in unselected regional population. J Am Coll Cardiol 1995; 26: 1529-1536.
  13. Cecchi F., Olivotto I., Montereggi A. et al. Prognostic value of nonsustained ventricular tachycardia and the potential role of amiodarone treatment in Hypertrophic cardiomiopathy. Heart 1998; 79: 331-336.
  14. Charron P., Dubourg O., Desnos M. et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophyc cardiomyopathy in a genotyped adult population. Circulation 1997; 96: 1: 214-219.
  15. Elliott P.M., Gimeno J.R., Mahon N.G. et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with Hypertrophic cardiomiopathy. Lancet 2001; 357: 420-424.
  16. Elliott P.M., Gimeno J.R., Tome M.T. et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933-1941.
  17. Elliott P.M., Poloniecki J., Dickie S. et al. Sudden death in Hypertrophic cardiomiopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
  18. Elliott P.M., Sharma S., Varnava A. et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596-1601.
  19. Fananaparzir L., Chang A.C., Epstein S.E. et al. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86: 730-740.
  20. Geske J.B., Sorajja P., Ommen S.R. et al. Left ventricular outflow tract gradient variability in Hypertrophic cardiomyopathy. Clin Cardiol 2009; 32: 397-402.
  21. Gimeno J.R., Tome-Esteban M., Lofiego C. et al. Exercise-induced ventricular arrhytmias and risk of sudden cardiac death in patients with Hypertrophic cardiomiopathy. Eur Heart J 2009; 30: 2599-2605.
  22. Harris K.M., Spirito P., Maron M.S. et al. Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216-225.
  23. Kisilbash A.M., Heinle S.K., Grayburn P.A. Spontaneous variability of left ventricular outflow tract gradient in hyperthropic obstructive cardiomyopathy. Circulation 1998; 97: 461-466.
  24. Maki S., Ikeda H., Muro A. et al. Predictors of sudden cardiac death in Hypertrophic cardiomiopathy. Am J Cardiol 1998; 82: 774-778.
  25. Marian A.J., Roberts R. Molecular genetic basis of Hypertrophic cardiomiopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998; 9: 88-99.
  26. Maron B.J. Hypertrophyc cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320.
  27. Maron B.J. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075.
  28. Maron B.J. Contemporary insights and strategies for risk stratification and prevention of sudden death in Hypertrophic cardiomiopathy. Circulation 2010; 121: 445-456.
  29. Maron B.J., Casey S.A., Poliac L.C. et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
  30. Maron B.J., Doerer J.J., Haas T.S. et al. Sudden death in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119: 1085-1092.
  31. Maron B.J., Gardin J.M., Flack J.M. et al. Prevalence of Hypertrophic cardiomiopathy a general population of young adults: Echocardiographic analisysis of 4111 subjects in the CARDIA study. Circulation 1995; 92: 785-789.
  32. Maron B.J., Haas T.S., Shannon K.M. et al. Long-term survival after cardiac arrest in Hypertrophic cardiomiopathy. Heart Rhythm 2009; 6: 993-997.
  33. Maron B.J., McKenna W.J., Danielson G.K. et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on Hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713.
  34. Maron B.J., Olivotto I., Spirito P. et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patients population. Circulation 2000; 102: 858-864.
  35. Maron B.J., Savage D.D., Wolfson J.K. et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertropic cardiomiopathy: a prospective study. Am J Cardiol 1981; 48: 252-257.
  36. Maron B.J., Semsarian C., Shen W.K. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with Hypertrophic cardiomiopathy. Heart Rhythm 2009; 6: 599-602.
  37. Maron B.J., Shen W.K., Link M.S. et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with Hypertrophic cardiomiopathy. N Engl J Med 2000; 342: 356-373.
  38. Maron B.J., Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomiopathy. J Cardiovasc Electrophysiol 2008; 19: 1118-1126.
  39. Maron B.J., Spirito P., Shen W.K. et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in Hypertrophic cardiomiopathy. JAMA 2007; 298: 405-412.
  40. Maron M.S., Appelbaum E., Harrigan C.J. et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1: 184-191.
  41. Maron M.S., Finley J.J., Bos J.M. et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in Hypertrophic cardiomiopathy. Circulation 2008; 118: 1541-1549.
  42. Maron M.S., Olivotto I., Betocchi S. Effect of left ventricular outflow tract obstruction on clinical outcome in hepertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
  43. McKenna W., Deanfield J., Faruqui A. et al. Prognosis in Hypertrophic cardiomiopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
  44. McLeod C.J., Ommen S.R., Ackerman M.J. et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive Hypertrophic cardiomyopathy. Eur Heart J 2007; 28: 2583-2588.
  45. Moolman J.C., Corfield V.A., Posen B. et al. Sudden death due to troponin T mutation. J Am Coll Cardiol 1997; 29: 549-555.
  46. Moon J.C., McKenna W.J., McCrohon J.A. et al. Toward clinical risk assessment in Hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-1567.
  47. Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.
  48. O'Hanlon R., Grasso A., Roughton M. et al. Prognostic significance of myocardial fibrosis in Hypertrophic cardiomiopathy. J Am Coll Cardiol 2010; 56: 876-874.
  49. Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of Hypertrophic cardiomiopathy. Circulation 2001; 104: 2517-2524.
  50. Olivotto I., Gistri R., Petrone P. et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315-321.
  51. Olivotto I., Maron B.J., Montereggi A. et al. Prognostic value of systemic blood pressure response during exercise in a community-based patients population with Hypertrophic cardiomiopathy. J Am Coll Cardiol 1999; 33: 2044-2051.
  52. Ommen S.R., Maron B.J., Olivotto I. et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomiopathy. J Am Coll Cardiol 2005; 46: 470-476.
  53. Rubinshtein R., Glockner J.F., Ommen S.R. et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced MRI in patients with Hypertrophic cardiomiopathy. Circ Heart Fail 2010; 3: 51-58.
  54. Sadoul N., Prasad K., Elliott P.M. et al. Prospective prognostic assesment of blood pressure response during exercise in patients with Hypertrophic cardiomiopathy. Circulation 1997; 96: 2987-2991.
  55. Semsarian C., Yu B., Ryce C. et al. Sudden cardiac death in familial Hypertrophic cardiomiopathy: are "benign" mutation really benign? Pathology 1997; 29: 305-308.
  56. Sorajja P., Nishimura R.A., Ommen S.R. et al. Use of echocardiography in patients with Hypertrophic cardiomiopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006; 19: 6: 788-795.
  57. Spirito P., Autore C., Rapezzi C. et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703-1710.
  58. Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular Hypertrophy and risk of sudden death in Hypertrophic cardiomiopathy. N Engl J Med 2000; 342: 1778-1785.
  59. Spirito P., Chiarella F., Carratino L. et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population. N Engl J Med 1989; 320: 749-755.
  60. Spirito P., Rapezzi C., Autore C. et al. Prognosis of asymptomatic patients with hypertrophic cardiomiopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-2747.
  61. Van Driest S.L., Ackerman M.J., Ommen S.R. et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in Hypertrophic cardiomiopathy. Circulation 2002; 106: 3085-3090.
  62. Van Driest S.L., Maron B.J., Ackerman M.J. From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing Hypertrophic cardiomiopathy. Heart 2004; 90: 7-8.
  63. Watkins H., Rosenzweig A., Hwang D.S. et al. Characteristics and prognostic implications of myosin missense mutations in familial Hypertrophic cardiomiopathy. N Engl J Med 1992; 326: 1108-1114.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.